Inhibikase Therapeutics, Inc.

NASDAQ:IKT

Biotechnology

Healthcare
$1.30 +3.57%

+$0.06 today

Market cap
$182.35M
Beta
0.97
P/E (TTM)
-3.4
EPS (TTM)
-$0.52
52W Low $1.33High $2.26

Volume 0.50M

Average 1.03M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$27.79M

FY 2025 · Annual

Investing Cash Flow

$2.05M

FY 2025 · Annual

Financing Cash Flow

$108.46M

FY 2025 · Annual

+4.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.79M)(18.05M)(19.03M)(27.52M)(48.26M)
Depreciation & Amortization06.72K177.4K26.27K60.5K
Deferred Income Tax00000
Stock-Based Compensation1.53M458.15K500.15K8.14M15.31M
Change in Working Capital(1.76M)171.18K234.76K204.93K55.93K
Accounts Receivables(110.14K)70.26K39.88K00
Inventory1.3M0000
Accounts Payables(630.9K)61.4K(504.41K)271.78K146.83K
Other Working Capital(2.33M)39.53K699.28K(66.85K)(90.9K)
Other Non-Cash Items721.63K67K31.54K05.05M
Operating Cash Flow(14.3M)(17.35M)(18.09M)(19.15M)(27.79M)
Capital Expenditures1(243.26K)(14.24K)0(13.4K)
Acquisitions (Net)0243.26K000
Purchases of Investments0(20.73M)(29.43M)(60.46M)(39.09M)
Sales of Investments04.96M41.1M23.45M41.6M
Other Investing Activities0(243.26K)000
Investing Cash Flow0(16.01M)11.66M(37M)2.05M
Debt Repayment(42.53K)(248.91K)000
Common Stock Issued41.14M44.14K8.54M103.48M108.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities8480000
Financing Cash Flow41.09M(204.77K)8.41M103.48M108.46M
Effect of Forex Changes00000
Net Change in Cash26.8M(33.56M)1.98M47.33M82.73M
Free Cash Flow(14.3M)(17.59M)(18.1M)(19.15M)(27.79M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$48.3M
+ D&A$60.5K
+ Stock-Based Comp$15.3M
+ Deferred Tax$0
+ Working Capital$55.9K
+ Other Non-Cash$5.0M
= Operating Cash Flow-$27.8M
- Capex-$13.4K
= Free Cash Flow-$27.8M

Analysis

FY2025 free cash flow is -$27.8M. FCF conversion is 57.6% of net income. Operating cash flow was -$27.8M, with capex of -$13.4K. The largest bridge item is Stock-Based Comp at $15.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
4Statement of changes in beneficial ownershipOct 21, 2026
3Initial statement of beneficial ownershipOct 21, 2026
8-KCurrent reportOct 20, 2026

Does IKT generate free cash flow?

Inhibikase Therapeutics, Inc. (IKT) generated -$27.79M of free cash flow in fiscal 2025.

How much operating cash flow does IKT produce?

Operating cash flow was -$27.79M, before capital expenditures of $13,396.00.